AlloVir

Allo Vir

Biotechnology, 1100 Winter St, Waltham, Massachusetts, 02451, United States, 51-200 Employees

allovir.com

  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is ALLOVIR

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-asso...

Read More

map
  • 1100 Winter St, Waltham, Massachusetts, 02451, United States Headquarters: 1100 Winter St, Waltham, Massachusetts, 02451, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $25 Million to $50 Million
  • Diana Brainard CEO:   Diana Brainard

industries-icon Industry: Biotechnology

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from ALLOVIR

AlloVir Org Chart and Mapping

Diana Brainard

Chief Executive Officer

Employees

Grant Knass

Clinical Trial Associate

Edward Miller

General Counse & Secretary

Jamie Bol

Quality Control Co-Op

Adam Fenimore

Senior Director, Head of External Manufacturing

Laurel Jahn

Senior Scientist, Cellular Process Development

Julia Camara

Senior Manager, Quality Systems, Documentation & Training

Alicia Wallis

Associate Director of Cellular Process Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AlloVir

Answer: AlloVir's headquarters are located at 1100 Winter St, Waltham, Massachusetts, 02451, United States

Answer: AlloVir's phone number is 61********

Answer: AlloVir's official website is https://allovir.com

Answer: AlloVir's revenue is $25 Million to $50 Million

Answer: AlloVir's SIC: 2836

Answer: AlloVir has 51-200 employees

Answer: AlloVir is in Biotechnology

Answer: AlloVir contact info: Phone number: 61******** Website: https://allovir.com

Answer: AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companys technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access